Everstone group to invest up to USD 50 million in Slayback Pharma LLC

Everstone Group will invest up to USD 50 million (about Rs 355 crore) in Slayback Pharma LLC. The new capital will be used to expand and further accelerate Slayback’s pipeline of complex generic and specialty pharmaceutical products. Prior to this, institutional investor KKR invested USD 60 million in Slayback in December 2016. Managing directors of Everstone Group – Arjun Oberoi and Puncham Mukim – will also join Slayback’s board of directors.